Table 2.
Types of PIK3CA mutations that were detected
| Patient | Treatment category | Exon 9 | Exon 20 |
| 1 | FAC/FEC | E545K | |
| 2 | FAC/FEC | H1047R | |
| 3 | FAC/FEC | H1047R | |
| 4 | FAC/FEC | E542K | |
| 5 | FAC/FEC | E545K | |
| 6 | FAC/FEC | H1047R | |
| 7 | FAC/FEC | E545K | |
| 8 | FAC/FEC | E545K | |
| 9 | FAC/FEC | H1047R | |
| 10 | FAC/FEC | E545K | |
| 11 | FAC/FEC | E545K | |
| 12 | FAC/FEC | E545K | |
| 13 | TFAC/TFEC | Q546R | |
| 14 | TFAC/TFEC | H1047T | |
| 15 | TFAC/TFEC | H1047R | |
| 16 | TFAC/TFEC | H1047R | |
| 17 | TFAC/TFEC | H1047R | |
| 18 | TFAC/TFEC | E545K | |
| 19 | TFAC/TFEC | E542K | |
| 20 | TFAC/TFEC | E542V | |
| 21 | TFAC/TFEC | G1049R | |
| 22 | TFAC/TFEC | H1047R | |
| 23 | TFAC/TFEC | H1047R |
Exon 1 mutations were also examined but no mutations were found. FAC, 5-fluoruracil, doxorubicin, and cyclophosphamide; FEC, 5-fluoruracil, epirubicin, and cyclophosphamide; PIK3CA, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide; TFAC, paclitaxel followed by 5-fluoruracil, doxorubicin, and cyclophosphamide; TFEC, paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide.